Founders Capital Management Sells 659 Shares of Johnson & Johnson (NYSE:JNJ)

Founders Capital Management lessened its position in shares of Johnson & Johnson (NYSE:JNJ) by 1.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 34,849 shares of the company’s stock after selling 659 shares during the quarter. Johnson & Johnson comprises about 3.2% of Founders Capital Management’s investment portfolio, making the stock its 13th largest position. Founders Capital Management’s holdings in Johnson & Johnson were worth $5,040,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the business. Asset Allocation & Management Company LLC bought a new position in shares of Johnson & Johnson in the 4th quarter worth $387,000. Parkside Advisors LLC boosted its holdings in Johnson & Johnson by 29.0% during the fourth quarter. Parkside Advisors LLC now owns 5,124 shares of the company’s stock worth $741,000 after buying an additional 1,153 shares during the last quarter. Kieckhefer Group LLC acquired a new position in shares of Johnson & Johnson during the 4th quarter worth about $275,000. Trust Co. of Toledo NA OH increased its stake in shares of Johnson & Johnson by 8.5% in the 4th quarter. Trust Co. of Toledo NA OH now owns 44,208 shares of the company’s stock valued at $6,393,000 after acquiring an additional 3,471 shares during the last quarter. Finally, Fiduciary Alliance LLC boosted its stake in Johnson & Johnson by 7.1% during the 4th quarter. Fiduciary Alliance LLC now owns 78,738 shares of the company’s stock worth $11,387,000 after acquiring an additional 5,245 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have commented on JNJ. Guggenheim upped their target price on shares of Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a research note on Wednesday, November 6th. Wells Fargo & Company lifted their target price on Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. Citigroup lowered their price target on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a report on Wednesday, December 11th. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a report on Wednesday, October 16th. Finally, Wolfe Research began coverage on Johnson & Johnson in a research note on Friday, November 15th. They set an “outperform” rating and a $190.00 target price for the company. Seven analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $174.71.

Insiders Place Their Bets

In related news, Director Mark A. Weinberger purchased 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The shares were bought at an average cost of $147.22 per share, with a total value of $147,220.00. Following the acquisition, the director now owns 1,000 shares of the company’s stock, valued at $147,220. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Up 0.7 %

JNJ stock traded up $1.02 during midday trading on Monday, hitting $143.08. The company’s stock had a trading volume of 3,925,855 shares, compared to its average volume of 7,365,605. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $168.85. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The company’s fifty day moving average price is $149.67 and its 200 day moving average price is $156.11. The stock has a market capitalization of $344.48 billion, a P/E ratio of 20.71, a PEG ratio of 2.52 and a beta of 0.51.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The company had revenue of $22.47 billion during the quarter, compared to analysts’ expectations of $22.17 billion. During the same quarter last year, the company posted $2.66 EPS. Johnson & Johnson’s quarterly revenue was up 5.2% compared to the same quarter last year. As a group, equities research analysts predict that Johnson & Johnson will post 9.94 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.47%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is 71.78%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.